We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multinational Initiative for MS Research

By Biotechdaily staff writers
Posted on 19 Aug 2005
Four teams from Europe and the United States have been awarded U.S.$15.6 million by the U.S. More...
National Multiple Sclerosis (MS) Society (New York, NY, USA) to lay the groundwork for clinical trials of new MS therapies over the next five years.

The teams are based at the University of Cambridge (Cambridge, UK), University College London (UK), Johns Hopkins University (Baltimore, MD, USA), the University of Wisconsin (Madison, USA).

MS involves a misdirected immune system attack against myelin, the coating on nerve fibers that speeds nerve signals and also destroys the underlying nerve fiber itself, causing symptoms like numbness, blindness, cognitive dysfunction, and paralysis. Recent progress in controlling immune attacks coupled with advances in neurosciences have made nervous tissue repair and protection emerging areas of MS research.

The repair teams are taking multifaceted approaches to protecting brain tissues and finding ways to rebuild the central nervous system. The teams will meet regularly to help foster synergy and collaboration. "Collaboration is critical to achieving our goals with these projects,” observed John R. Richert, M.D., vice president of R&D clinical programs at the National MS Society. "We know that sharing ideas and key findings will get us to the finish line that much faster.”

Neurologist Dr. Peter A. Calabresi (Johns Hopkins) and his team are searching for better ways to detect and quantify tissue injury in MS and are testing agents that may protect the nervous system from further damage. The international team headed by Prof. Charles French-Constant (University of Cambridge) is focusing on restoring myelin by identifying and amplifying natural repair factors in the brain and by attempting transplantation of replacement cells.

Dr. Gavin Giovannoni (University College London) and his team are attempting to turn cells into vehicles that will deliver repair molecules to sites of injury in the brain, and screening molecules for their protective properties. Prof. Ian D. Duncan (University of Wisconsin) is leading a team to develop better imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI) to visualize myelin and nerve fiber damage, and to detect its repair. They are also exploring cell transplantation techniques.




Related Links:
National Multiple Sclerosis Society

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Pipette Calibration System
Artel PCS®
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.